Access Hope CRO is the first CRO dedicated solely to facilitating Right to Try access programs at scale for drug developers, and the treatment community.
Access Hope CRO Founder, Richard Garr is an attorney, 17-year veteran of the biopharmaceutical industry, and father of a child who has benefited twice from investigational treatments outside of the traditional clinical trial environment. If you woulde like to read more about Richard and his family's story click here. He brings both an industry and a caregiver perspective to the vital issue of safe, ethical and legal expanded patient access to potentially life-saving investigational treatments. As such, he was deeply involved in drafting the template for Right to Try legislation, now law in 41 states, as well as the federal Trickett Wendler, Frank Mongiello, Jordan McLinn, and Mathew Bellina Right to Try Act, which passed in 2018.
He founded Access Hope CRO to provide the infrastructure to facilitate turn-key scalable Right to Try treatment solutions for patients, drug developers, and clinicians.
Putting the choice in your hands.
Our mission is to create access to experimental drugs for patients with life threatening or severely disabling diseases outside of traditional clinical trials.
The promise of Right to Try for patients is to create access to experimental drugs. The promise of Right to Try for the treatment community is to provide physicians with possible treatment options and hope for their most needy patients. The promise of Right to Try for the biopharma industry is the ability to tap into a new source of Real World Data to create pre-approval insights that will help shape and guide the ever increasing burdens of drug development. Our vision at Access Hope CRO is to enable the promise of Right to Try for all three communities.